Markets
JNJ

Johnson & Johnson's Revenue and Earnings Slipped in the Second Quarter

It wasn't a pretty second quarter for Johnson & Johnson (NYSE: JNJ), but the issues caused by the coronavirus pandemic were expected. In fact, the sales and earnings declines weren't as bad the healthcare conglomerate was expecting, which led management to raise its 2020 guidance.

All told, Johnson & Johnson's sales slipped 10.8% to $18.3 billion. Not surprisingly, given all the canceled surgeries, its medical devices segment was hit hardest with sales down 33.9%. Sales of consumer health products dropped 7% as people cut back on purchases of skin health and beauty care products. The pharmaceutical division was the only one with a year-over-year sales increase, although drug sales only rose by 2.1% as changes in currency exchange rates cut into their growth by 1.8 percentage points.

Second-quarter earnings came in at $1.36 per share, down 34.6% year over year. The company did a good job controlling its selling, marketing, and administrative expenses, but earnings dropped faster than revenue because Johnson & Johnson continued to spend on research and development, including incurring at-risk manufacturing costs for its coronavirus vaccine candidate.

Doctor talking to a patient

Image source: Getty Images.

Even as bad as the second-quarter sales and earnings look on a year-over-year basis, the results, especially for the medical devices segment, were better than management had expected when first-quarter results were revealed in April.

At this point, management thinks it can reach 2020 sales of $79.9 billion to $81.4 billion, which would be a decrease of 0.8% to 2.6% from last year. Its previous guidance forecast that sales would drop by 2% to 5.5% in 2020.

On the bottom line, management expects 2020 earnings per share in the $7.75 to $7.95 range, higher than the $7.50 to $7.90 range management predicted in April, but still 8.4% to 10.7% lower than the company's 2019 EPS.

10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 2, 2020

 

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

JNJ

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More